Trial Profile
ABT 072 vs ABT 333 in patients with hepatitis C also receiving peginterferon alfa-2a + ribavirin: a dose-ranging study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 May 2012
Price :
$35
*
At a glance
- Drugs ABT 072 (Primary) ; Dasabuvir; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 10 May 2012 New trial record
- 22 Apr 2012 Interim results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.